Similar articles

• ChlVPP: reducing toxicity in the treatment of Hodgkin's disease.

  Mansi JL. Mansi JL. Eur J Cancer. 1992;28A(8-9):1411-3. doi: 10.1016/0959-8049(92)90532-7. Eur J Cancer. 1992. PMID: 1515260 No abstract available.
• ChlVPP chemotherapy in advanced Hodgkin's disease.

  McKendrick JJ, Mead GM, Sweetenham J, Jones DH, Williams CJ, Ryall R, Whitehouse JM. McKendrick JJ, et al. Eur J Cancer Clin Oncol. 1989 Mar;25(3):557-61. doi: 10.1016/0277-5379(89)90270-8. Eur J Cancer Clin Oncol. 1989. PMID: 2703008
• [Treatment outcome of advanced Hodgkin's disease based on using an alternating program ChLVPP (chlorambucil, vinblastine, procarbazine, prednisone) and ABV (doxorubicin, bleomycin, vinblastine)].

  Komarnicki M, Balcerzak A, Górski P, Pawlak L, Hansz J. Komarnicki M, et al. Acta Haematol Pol. 1994;25(4):363-8. Acta Haematol Pol. 1994. PMID: 7531381 Polish.
• The cure of Hodgkin's disease with drugs.

  DeVita VT Jr, Hubbard SM, Moxley JH 3rd. DeVita VT Jr, et al. Adv Intern Med. 1983;28:277-302. Adv Intern Med. 1983. PMID: 6188346 Review. No abstract available.
• [A suggested program of combined treatment of Hodgkin's disease in children].

  Balwierz W, Armata J, Moryl-Bujakowska A, Strzeszyński J, Depowska T. Balwierz W, et al. Pol Tyg Lek. 1988 Dec 12;43(50):1637-40. Pol Tyg Lek. 1988. PMID: 2476790 Review. Polish. No abstract available.